Back to results
US 2024/0288432 A1Published application
Predicting cancer relapse
AssigneeArocell AB
InventorsStaffan ERIKSSON, Per VENGE
Life of this patent
Estimating the term…
Abstract
The invention relates to predicting cancer relapse or predicting patient survival by determining a level of serum thymidine kinase 1 (STK1) material in a body sample from a patient diagnosed with hematological cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The determined level of STK1 material is compared with a threshold value selected based on an age of the patient. Cancer relapse is then predicted based on the comparison.
Claims25
-23. (canceled)
A method for predicting cancer relapse comprising:
- determining a level of serum thymidine kinase 1 (STK1) material in a serum sample or a plasma sample from a patient diagnosed with hematological cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1;
- comparing the determined level of STK1 material with a threshold value selected based on an age of the patient;
- and
- predicting cancer relapse of the patient based on the comparison.
1 more element
Dependencies are inferred from the claim text.